https://beta.crstoday.com/news/eyenovia-announces-new-25-million-credit-facility-with-silicon-valley-bank/2479182/daily0.7https://beta.crstoday.com/news/rayners-rayone-aspheric-preloaded-iol-launches-in-china/2479183/daily0.7https://beta.crstoday.com/news/sinopharms-covid-19-vaccine-granted-who-emergency-listing/2479184/daily0.7https://beta.crstoday.com/news/clearside-biomedical-announces-multiple-poster-presentations-at-arvo/2479185/daily0.7https://beta.crstoday.com/news/shamir-and-alpine-f1-team-form-partnership/2479181/daily0.7https://beta.crstoday.com/news/new-partnership-expands-alcons-in-office-dry-eye-and-ocular-health-portfolio/2479180/daily0.7https://beta.crstoday.com/news/tarsus-pharmaceuticals-initiates-saturn-2-phase-3-trial-evaluating-the-safety-and-efficacy-of-tp-03-for-the-treatment-of-demodex-blepharitis/2479179/daily0.7https://beta.crstoday.com/news/johnson-johnson-vision-announces-the-approval-of-tecnis-synergy-and-tecnis-synergy-toric-ii-iols-in-the-us/2479178/daily0.7https://beta.crstoday.com/news/gyroscope-therapeutics-postpones-initial-public-offering/2479176/daily0.7https://beta.crstoday.com/news/melling-medical-to-distribute-optos-technology-to-federal-health-facilities/2479175/daily0.7https://beta.crstoday.com/news/belkin-laser-completes-enrollment-of-its-glaurious-pivotal-trial-for-glaucoma-laser-treatment-in-seconds/2479174/daily0.7https://beta.crstoday.com/news/ocular-innovations-powered-by-engage-launches-exclusive-ophthalmology-video-content-for-patient-facing-ophthalmology-solution-delivering-content-rich-touchpoints-through-frictionless-mobile/2483614/daily0.7https://beta.crstoday.com/news/coopervision-specialty-eye-care-aims-to-boost-fitting-confidence-through-new-educational-resources/2483613/daily0.7https://beta.crstoday.com/news/surface-ophthalmics-chronic-dry-eye-study-reaches-50-enrollment-milestone/2479173/daily0.7https://beta.crstoday.com/news/verana-health-study-demonstrates-promise-of-real-world-data-in-ophthalmic-clinical-development/2479172/daily0.7https://beta.crstoday.com/news/coopervision-expands-prescription-options-for-biofinity-xr-toric-contact-lenses/2479170/daily0.7https://beta.crstoday.com/news/eversight-names-diane-hollingsworth-president-ceo/2479171/daily0.7https://beta.crstoday.com/news/rayner-launches-the-plus1-emv-campaign-on-monovision-education/2479168/daily0.7https://beta.crstoday.com/news/nicox-partners-with-laboratorios-grin-to-bring-zerviate-to-mexico/2479169/daily0.7https://beta.crstoday.com/news/ceyeber-announces-advisory-board-of-world-renowned-ophthalmologists/2479167/daily0.7https://beta.crstoday.com/news/ocular-therapeutix-fulfills-post-marketing-approval-requirements-for-resure-sealant/2479164/daily0.7https://beta.crstoday.com/news/proqr-therapeutics-and-yarrow-biotechnology-announce-exclusive-license-and-discovery-collaboration-for-undisclosed-ophthalmic-target/2479165/daily0.7https://beta.crstoday.com/news/nicoxs-licensee-bausch-lomb-launches-vyzulta-in-taiwan-and-receives-approval-in-qatar/2479163/daily0.7https://beta.crstoday.com/news/tarsus-pharmaceuticals-presents-results-of-atlas-study-demonstrating-the-functional-and-psychosocial-impact-of-demodex-blepharitis/2479161/daily0.7https://beta.crstoday.com/news/pfizer-biontech-seek-eu-nod-to-allow-covid-19-vaccine-use-in-younger-teens/2479158/daily0.7https://beta.crstoday.com/news/ophtec-introduces-precizon-presbyopic-toric-iol/2479159/daily0.7https://beta.crstoday.com/news/mallinckrodt-presents-data-evaluating-acthar-gel-for-the-treatment-of-severe-keratitis-at-arvo/2479153/daily0.7https://beta.crstoday.com/news/new-alcon-data-on-contact-lens-dry-eye-and-ocular-health-to-be-presented-at-arvo-2021/2479151/daily0.7https://beta.crstoday.com/news/johnson-johnson-vision-presents-new-myopia-cataract-refractive-and-meibomian-gland-dysfunction-data-at-arvo-2021/2479152/daily0.7https://beta.crstoday.com/news/alcon-presents-highlights-of-arvo-2021-data/2479149/daily0.7https://beta.crstoday.com/news/refractive-surgery-council-reports-nearly-30-rise-in-laser-vision-correction-procedures-year-over-year/2479148/daily0.7https://beta.crstoday.com/news/the-countess-of-wessex-praises-work-of-sight-saving-charity-orbis-during-pandemic/2479147/daily0.7https://beta.crstoday.com/news/ocular-therapeutix-to-present-preclinical-and-clinical-data-at-arvo/2479146/daily0.7https://beta.crstoday.com/news/nova-eye-medical-announces-first-patient-enrolled-in-magic-multicenter-canaloplasty-trial-for-glaucoma/2479145/daily0.7https://beta.crstoday.com/news/lumenis-receives-fda-approval-for-its-ipl-device-to-manage-dry-eye-disease-and-launches-optilight/2479143/daily0.7https://beta.crstoday.com/news/okogen-announces-interim-analysis-results-from-ruby-phase-2-trial-for-acute-adenoviral-conjunctivitis-drug-candidate/2479140/daily0.7https://beta.crstoday.com/news/coopervision-reveals-new-ocular-research-at-arvo-2021-virtual-meeting/2479142/daily0.7https://beta.crstoday.com/news/alcon-to-acquire-us-commercialization-rights-to-ophthalmic-eye-drop-simbrinza/2479138/daily0.7https://beta.crstoday.com/news/bausch-lomb-will-present-new-scientific-data-and-analyses-on-products-and-pipeline-programs-during-arvo-2021/2479139/daily0.7https://beta.crstoday.com/news/onesight-seeks-volunteer-ods-for-charitable-clinics/2479133/daily0.7https://beta.crstoday.com/news/aerie-pharmaceuticals-completes-enrollment-of-its-phase-2b-clinical-trial-of-ar-15512-trpm8-agonist-for-the-treatment-of-patients-with-dry-eye-disease/2479134/daily0.7https://beta.crstoday.com/news/alcon-launches-systane-hydration-multi-dose-preservative-free-lubricant-eye-drops-in-the-u-s/2479131/daily0.7https://beta.crstoday.com/news/ophthalmic-world-leaders-announces-development-and-networking-program-for-executives-seeking-corporate-board-positions/2479130/daily0.7https://beta.crstoday.com/news/dorc-launches-eva-aveta-trocar-cannula-system/2479129/daily0.7https://beta.crstoday.com/news/aerie-pharmaceuticals-announces-presentations-at-the-2021-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting/2479128/daily0.7https://beta.crstoday.com/news/backlog-of-6-million-cataract-surgeries-will-help-drive-iol-market-through-2026/2479127/daily0.7https://beta.crstoday.com/news/eyemate-system-for-remote-glaucoma-management-obtains-fda-breakthrough-device-designation/2479126/daily0.7https://beta.crstoday.com/news/novaliq-announces-more-than-half-of-patients-enrolled-in-cyclasol-phase-3-dry-eye-disease-trial-essence-2/2479125/daily0.7https://beta.crstoday.com/news/hoya-vision-care-releases-results-of-3-year-miyosmart-spectacle-lens-follow-up-study/2479124/daily0.7https://beta.crstoday.com/news/sifi-initiates-patient-enrollment-in-phase-2-trial-evaluating-pro-ocular-in-dry-eye-disease/2479120/daily0.7https://beta.crstoday.com/news/haag-streit-diagnostics-to-hold-biometry-focus-month-online-education-events/2479121/daily0.7https://beta.crstoday.com/news/aldeyra-therapeutics-achieves-statistical-significance-for-primary-and-secondary-endpoints-in-phase-3-trial-of-reproxalap-in-allergic-conjunctivitis/2479122/daily0.7https://beta.crstoday.com/news/allergan-to-share-new-data-highlighting-latest-advancements-in-eye-care-at-arvo-2021/2479116/daily0.7https://beta.crstoday.com/news/johnson-johnson-vision-receives-approval-in-canada-for-first-drug-releasing-contact-lens-for-vision-correction-and-allergic-eye-itch/2479117/daily0.7https://beta.crstoday.com/news/foundation-fighting-blindness-appoints-claire-m-gelfman-phd-as-chief-scientific-officer/2479118/daily0.7https://beta.crstoday.com/news/us-patent-office-issues-notice-of-allowance-for-nicoxs-latanoprostene-bunod-in-normal-tension-glaucoma/2479119/daily0.7https://beta.crstoday.com/news/glaukos-announces-global-licensing-agreement-amendment-with-intratus-to-include-the-treatment-of-presbyopia/2479115/daily0.7https://beta.crstoday.com/news/oertli-launches-new-silicone-application-adapter/2479114/daily0.7https://beta.crstoday.com/news/chmp-recommends-eu-approval-of-enspryng-satralizumab-for-neuromyelitis-optica-spectrum-disorder-nmosd/2479111/daily0.7https://beta.crstoday.com/news/orasis-pharmaceuticals-appoints-industry-veteran-paul-smith-as-president-and-chief-operating-officer/2479112/daily0.7https://beta.crstoday.com/news/more-than-200-exhibiting-companies-commit-to-vision-expo-east-2021/2479110/daily0.7https://beta.crstoday.com/news/nicoxs-ncx-4251-mississippi-phase-2b-blepharitis-trial-reaches-50-enrollment/2479109/daily0.7https://beta.crstoday.com/news/proqr-announces-virtual-presentation-of-phase-1-2-sepofarsen-extension-trial-data-at-arvo-2021/2479108/daily0.7https://beta.crstoday.com/news/hillrom-launches-digital-physical-assessment-innovations-to-advance-connected-care/2479106/daily0.7https://beta.crstoday.com/news/market-scope-us-cataract-pharmaceuticals-evolve-in-drug-delivery/2479107/daily0.7https://beta.crstoday.com/news/nidek-marks-50th-anniversary-and-renews-logo/2479104/daily0.7https://beta.crstoday.com/news/oertli-launches-new-generation-of-their-os-4-surgical-platform/2479105/daily0.7https://beta.crstoday.com/news/us-patents-for-nicoxs-vyzulta-latanoprostene-bunod-eligible-for-patent-term-extension/2479103/daily0.7https://beta.crstoday.com/news/johnson-johnson-vision-receives-fda-clearance-and-ce-mark-for-next-generation-phacoemulsification-machine-veritas-vision-system/2479100/daily0.7https://beta.crstoday.com/news/johnson-johnson-vision-introduces-acuvue-abiliti-to-address-myopia-in-children/2479101/daily0.7https://beta.crstoday.com/news/eyecare-partners-promotes-david-clark-to-chief-executive-officer/2479099/daily0.7https://beta.crstoday.com/news/texas-eye-and-cataract-clinic-now-accepting-bitcoin-for-lasik-surgery/2479096/daily0.7https://beta.crstoday.com/news/ora-appoints-david-p-bingaman-dvm-phd-in-newly-created-chief-development-officer-position/2479097/daily0.7https://beta.crstoday.com/news/mipt-and-harvard-researchers-grow-stem-cells-to-cure-glaucoma-in-mice/2479095/daily0.7https://beta.crstoday.com/news/next-generation-covid-vaccines-have-many-different-targets/2479094/daily0.7https://beta.crstoday.com/news/nanodropper-completes-1-4-million-seed-funding-round/2479092/daily0.7https://beta.crstoday.com/news/palatin-announces-two-presentations-at-the-2021-association-for-research-in-vision-and-ophthalmology-arvo-annual-meeting/2479093/daily0.7https://beta.crstoday.com/news/nova-eye-24-month-itrack-data-demonstrate-real-world-efficacy-of-canaloplasty-as-both-a-standalone-and-combined-migs-procedure/2479091/daily0.7https://beta.crstoday.com/news/aerie-pharmaceuticals-receives-marketing-authorisation-of-roclanda-in-great-britain/2479089/daily0.7https://beta.crstoday.com/news/pfizer-ceo-predicts-third-covid-19-vaccine-booster-likely-needed-within-year/2479086/daily0.7https://beta.crstoday.com/news/bausch-health-announces-vyzulta-is-now-approved-in-brazil/2479084/daily0.7https://beta.crstoday.com/news/quantel-medical-launches-dry-eye-information-website-for-patients/2479085/daily0.7https://beta.crstoday.com/news/protokinetix-engages-multi-national-partner-for-formulation-of-topical-drug-to-treat-ded-ocular-inflammation/2479083/daily0.7https://beta.crstoday.com/news/katena-products-acquires-ophthalmic-instrument-maker-asico/2479080/daily0.7https://beta.crstoday.com/news/qlaris-bio-enrolls-first-patient-in-phase-1-2-studies-of-investigational-glaucoma-drug-qls-101/2479081/daily0.7https://beta.crstoday.com/news/proqr-announces-publication-in-nature-medicine-for-sepofarsen-in-leber-congenital-amaurosis-10/2479077/daily0.7https://beta.crstoday.com/news/study-glaucoma-may-be-more-than-just-an-issue-of-eye-pressure/2479078/daily0.7https://beta.crstoday.com/news/modernas-covid-19-vaccine-shows-sustained-protection-at-six-months/2479079/daily0.7https://beta.crstoday.com/news/national-optometric-association-to-host-regional-meeting-at-vision-expo-east-2021/2479076/daily0.7https://beta.crstoday.com/news/feds-call-halt-to-johnson-johnson-covid-19-vaccine-rollout-after-extremely-rare-blood-clot-cases/2479070/daily0.7https://beta.crstoday.com/news/roche-regenerons-regen-cov-cuts-symptomatic-covid-19-by-81-among-household-contacts/2479071/daily0.7https://beta.crstoday.com/news/bausch-lomb-announces-topline-results-from-the-first-phase-3-trial-of-nov03-in-dry-eye-disease-associated-with-mgd/2479072/daily0.7https://beta.crstoday.com/news/alcon-canada-introduces-uv-only-iols-for-acrysof-iq-panoptix-and-acrysof-iq-vivity-portfolios/2479066/daily0.7https://beta.crstoday.com/news/santen-announces-global-research-initiative-to-study-and-develop-new-treatments-for-glaucoma/2479067/daily0.7https://beta.crstoday.com/news/pfizer-biontech-seek-expanded-emergency-use-of-covid-19-vaccine-in-younger-adolescents/2479068/daily0.7https://beta.crstoday.com/news/allergan-launches-new-consumer-ad-campaign-for-restasis/2479065/daily0.7https://beta.crstoday.com/news/nei-joins-call-for-standardization-of-ophthalmic-imaging-devices/2479064/daily0.7https://beta.crstoday.com/news/prior-authorization-and-the-covid-19-pandemic-causing-even-more-patient-care-delays-and-treatment-abandonment/2483612/daily0.7https://beta.crstoday.com/news/essilor-to-present-new-results-for-its-stellest-lens-for-children-with-myopia/2479062/daily0.7https://beta.crstoday.com/news/american-academy-of-ophthalmology-urges-ophthalmic-equipment-manufacturers-to-standardize-digital-imaging/2479061/daily0.7https://beta.crstoday.com/news/fda-approves-bausch-lomb-clearvisc-dispersive-ophthalmic-viscosurgical-device-ovd/2479058/daily0.7https://beta.crstoday.com/news/systematic-review-of-standalone-istent-trabecular-micro-bypass-glaucoma-surgery/2479056/daily0.7https://beta.crstoday.com/news/johnson-johnson-takes-charge-of-emergent-covid-19-vaccine-manufacturing-site/2479052/daily0.7https://beta.crstoday.com/news/onesight-partners-with-anthem-blue-cross-and-blue-shield-foundation-to-provide-free-eye-exams-and-glasses-in-cincinnati/2479049/daily0.7https://beta.crstoday.com/news/infectious-disease-researcher-appointed-inaugural-chief-scientific-officer-at-mass-eye-and-ear/2479047/daily0.7https://beta.crstoday.com/news/covid-19-accelerates-trend-of-hospitals-acquiring-ambulatory-surgery-centers/2479048/daily0.7https://beta.crstoday.com/news/johnson-johnson-begins-testing-covid-19-vaccine-in-adolescents/2479045/daily0.7https://beta.crstoday.com/news/new-educational-resource-on-importance-of-eye-protection-in-sports-recreational-activitites/2479046/daily0.7https://beta.crstoday.com/news/horizon-therapeutics-to-resupply-market-with-tepezza-for-the-treatment-of-thyroid-eye-disease-ted-beginning-in-april/2479043/daily0.7https://beta.crstoday.com/news/large-employers-are-eyeing-on-site-covid-19-vaccines-survey-shows/2479044/daily0.7https://beta.crstoday.com/news/eyenovia-announces-appointment-of-julia-haller-md-to-its-board-of-directors/2479041/daily0.7https://beta.crstoday.com/news/santen-launches-puralid-lipogel/2479040/daily0.7https://beta.crstoday.com/news/zeiss-opens-new-high-tech-center-in-san-francisco-bay-area/2479038/daily0.7https://beta.crstoday.com/news/nanoform-and-nacuity-pharmaceuticals-sign-technology-proof-of-concept-agreement-for-two-ophthalmic-drug-candidates/2479035/daily0.7https://beta.crstoday.com/news/affamed-therapeutics-and-sifi-announce-joint-venture-to-serve-greater-china-market/2479036/daily0.7https://beta.crstoday.com/news/surface-ophthalmics-announces-preeya-k-gupta-md-as-chief-medical-advisor/2479032/daily0.7https://beta.crstoday.com/news/study-drinking-wine-may-help-protect-against-cataracts/2479033/daily0.7https://beta.crstoday.com/news/umass-medical-school-and-aeye-health-leverage-ai-to-help-family-doctors-screen-and-refer-patients-with-eye-conditions-to-specialists/2479031/daily0.7https://beta.crstoday.com/news/aerie-pharmaceuticals-announces-publication-of-peer-reviewed-paper-evaluating-the-treatment-effect-of-netarsudil-on-outflow-function-in-steroid-induced-glaucoma/2479030/daily0.7https://beta.crstoday.com/news/nursing-homes-see-96-percent-decline-in-covid-cases-since-vaccine-rollout/2479027/daily0.7https://beta.crstoday.com/news/pfizer-moderna-covid-19-vaccines-show-high-efficacy-in-first-us-real-world-study/2479028/daily0.7https://beta.crstoday.com/news/affamed-therapeutics-completes-170-million-series-b-financing-to-further-development-of-ophthalmic-and-neuroscience-pipeline/2479029/daily0.7https://beta.crstoday.com/news/tarsus-pharmaceuticals-and-lianbio-announce-strategic-partnership-to-develop-and-commercialize-tp-03-drug-candidate-in-greater-china/2479026/daily0.7https://beta.crstoday.com/news/report-contact-lenses-to-advance-well-beyond-refractive-error-correction/2479024/daily0.7https://beta.crstoday.com/news/eu-regulator-clears-manufacturing-sites-to-boost-covid-19-vaccine-supply/2479025/daily0.7https://beta.crstoday.com/news/neurolens-announces-the-launch-of-the-nmd2-measurement-device/2479022/daily0.7https://beta.crstoday.com/news/refractive-surgery-council-reports-demand-for-laser-vision-correction-procedures-increases-during-covid-19-pandemic/2479020/daily0.7https://beta.crstoday.com/news/oasis-medical-launches-cyber-platform-my-oasis-to-support-dry-eye-clinics/2479021/daily0.7https://beta.crstoday.com/news/fda-approves-rayners-rayone-emv-iol/2479019/daily0.7https://beta.crstoday.com/news/pfizer-biontech-initiate-study-of-covid-19-vaccine-in-children-under-12/2479017/daily0.7https://beta.crstoday.com/news/intel-ai-powered-backpack-helps-visually-impaired-navigate-world/2479014/daily0.7https://beta.crstoday.com/news/neuroptics-launches-pupillometry-program-at-vanderbilt-university-medical-center/2479015/daily0.7https://beta.crstoday.com/news/visus-therapeutics-initiates-phase-2-clinical-trial-of-brimochol-for-the-treatment-of-presbyopia/2479013/daily0.7https://beta.crstoday.com/news/jasmine-pachnanda-named-senior-vice-president-for-ceo-leadership-alliance-will-lead-socal-ai-initiative/2479012/daily0.7https://beta.crstoday.com/news/johnson-johnson-vision-receives-approval-in-japan-for-first-drug-releasing-combination-contact-lens-for-vision-correction-and-allergic-eye-itch/2479010/daily0.7https://beta.crstoday.com/news/aura-biosciences-names-mark-de-rosch-phd-chief-operating-officer/2479008/daily0.7https://beta.crstoday.com/news/uplinza-approved-in-japan-for-the-prevention-of-relapses-of-neuromyelitis-optica-spectrum-disorder-nmosd/2479009/daily0.7https://beta.crstoday.com/news/judy-f-gordon-dvm-founder-of-clinreg-consulting-services-retires/2479004/daily0.7https://beta.crstoday.com/news/vsy-biotechnology-signs-agreement-with-wakamoto-pharmaceutical-on-intraocular-lens-products/2479003/daily0.7https://beta.crstoday.com/news/nicoxs-ncx-470-mont-blanc-phase-3-glaucoma-trial-reaches-50-enrollment-milestone/2478999/daily0.7https://beta.crstoday.com/news/santen-emea-appoints-dr-ioana-grobeiu-as-vice-president-medical-affairs/2479000/daily0.7https://beta.crstoday.com/news/eyenovia-and-eversana-announce-partnership-to-support-the-potential-launch-and-commercialization-of-mydcombi-for-mydriasis/2479001/daily0.7https://beta.crstoday.com/news/adhawk-microsystems-launches-adhawk-mindlink-eye-tracking-research/2479002/daily0.7https://beta.crstoday.com/news/new-open-access-ophthalmology-journal-now-live/2478998/daily0.7https://beta.crstoday.com/news/nidek-launches-rt-6100-cb-for-windows-to-enhance-refraction-workflow/2478994/daily0.7https://beta.crstoday.com/news/astrazenecas-covid-19-vaccine-shows-79-efficacy-in-pivotal-us-study/2478995/daily0.7https://beta.crstoday.com/news/sifi-recevies-marketing-authorizations-for-ophthalmic-products-in-in-turkey/2478996/daily0.7https://beta.crstoday.com/news/magic-trial-to-assess-factors-that-impact-clinical-outcomes-of-ab-interno-canaloplasty/2478993/daily0.7https://beta.crstoday.com/news/national-eye-institute-launches-data-portal-for-macular-degeneration-research/2478992/daily0.7https://beta.crstoday.com/news/senate-narrowly-confirms-becerra-as-hhs-secretary/2478991/daily0.7https://beta.crstoday.com/news/emas-blood-clot-review-exonerates-astrazeneca-covid-19-vaccine-but-monitoring-continues/2478990/daily0.7https://beta.crstoday.com/news/bjo-publishes-new-data-on-clearside-biomedicals-investigational-treatment-xipere/2478989/daily0.7https://beta.crstoday.com/news/hk-scientist-develops-retinal-scan-technology-to-identify-early-childhood-autism/2478987/daily0.7https://beta.crstoday.com/news/hovione-completes-phase-2-clinical-trial-of-first-minocycline-ophthalmic-showing-promise-in-dry-eye-disease-associated-with-inflamed-mgd/2478986/daily0.7https://beta.crstoday.com/news/mediprint-ophthalmics-announces-successful-completion-of-its-sight-1-phase-2a-clinical-study/2478983/daily0.7https://beta.crstoday.com/news/new-study-finds-significant-improvements-in-ded-following-use-of-eye-eco-tranquileyes-xl-and-tranquilvibes-hydrating-masks/2478984/daily0.7https://beta.crstoday.com/news/the-world-council-of-optometry-and-coopervision-partner-to-define-a-standard-of-care-to-treat-myopia-progression/2478985/daily0.7https://beta.crstoday.com/news/studies-demonstrate-the-efficacy-and-safety-of-eyenovia-map-fixed-combination-tropicamide-phenylephrine-product-for-mydriasis/2478982/daily0.7https://beta.crstoday.com/news/rabb-venable-excellence-in-ophthalmology-program-abstract-submission-open-until-march-31/2478981/daily0.7https://beta.crstoday.com/news/corneagen-names-bernie-iliakis-president/2478979/daily0.7https://beta.crstoday.com/news/novasight-announces-first-pivotal-study-for-lazy-eye-digital-treatment-against-gold-standard-patching/2478980/daily0.7https://beta.crstoday.com/news/moderna-gives-first-vaccine-shots-to-young-kids-as-part-of-covid-19-study/2478978/daily0.7https://beta.crstoday.com/news/kala-pharmaceuticals-announces-preferred-position-for-eysuvis-on-cigna/2478977/daily0.7https://beta.crstoday.com/news/ema-continues-safety-probe-of-astrazenecas-covid-19-vaccine-as-more-countries-halt-use/2478974/daily0.7https://beta.crstoday.com/news/magewell-video-capture-devices-help-non-profit-eyecare-organization-remotely-train-retinal-surgeons-worldwide/2478975/daily0.7https://beta.crstoday.com/news/new-icare-home2-self-tonometer-enables-accurate-eye-pressure-measurement-by-glaucoma-patients/2478976/daily0.7https://beta.crstoday.com/news/newly-formed-ophthalmology-foundation-will-improve-global-eye-care-through-education/2478972/daily0.7https://beta.crstoday.com/news/visus-therapeutics-announces-fda-acceptance-of-ind-for-presbyopia-correcting-eye-drop/2478973/daily0.7https://beta.crstoday.com/news/eyeyon-medical-raises-25-million-in-series-c-to-transform-corneal-care/2478969/daily0.7https://beta.crstoday.com/news/jjs-coronavirus-vaccine-garners-who-emergency-use-listing/2478968/daily0.7https://beta.crstoday.com/news/ocuphire-announces-mira-2-phase-3-registration-trial-for-the-reversal-of-mydriasis-meets-primary-endpoint/2478967/daily0.7https://beta.crstoday.com/news/bausch-health-announces-cfo-succession-plan/2478964/daily0.7https://beta.crstoday.com/news/more-data-point-to-pfizer-biontech-vaccine-cutting-covid-19-transmission-rates/2478965/daily0.7https://beta.crstoday.com/news/eu-greenlights-jjs-coronavirus-vaccine/2478966/daily0.7https://beta.crstoday.com/news/aao-looks-like-the-home-office-is-here-to-stay-heres-how-to-protect-your-eyes/2478962/daily0.7https://beta.crstoday.com/news/ascrs-introduces-richard-l-lindstrom-lecture-for-2021-annual-meeting/2478960/daily0.7https://beta.crstoday.com/news/lillys-bamlanivimab-etesevimab-cut-hospitalizations-deaths-in-high-risk-covid-19-patients/2478961/daily0.7https://beta.crstoday.com/news/core-offers-tips-on-seeking-eye-care-during-the-pandemic-provides-free-infographics-for-ecps-to-use-with-patients/2478959/daily0.7https://beta.crstoday.com/news/new-study-links-protein-causing-alzheimers-disease-with-common-sight-loss/2478957/daily0.7https://beta.crstoday.com/news/fda-clears-oculus-pentacam-axl-wave/2478958/daily0.7https://beta.crstoday.com/news/visus-therapeutics-announces-36-million-series-a-financing-to-advance-development-of-novel-presbyopia-correcting-eye-drop/2478952/daily0.7https://beta.crstoday.com/news/pfizer-biontechs-covid-19-vaccine-neutralizes-brazil-variant-in-lab-study/2478953/daily0.7https://beta.crstoday.com/news/over-20000-screened-for-glaucoma-in-india-and-nigeria-thanks-to-joint-initiative-keep-sight/2478954/daily0.7https://beta.crstoday.com/news/allergan-launches-glaucoma-in-perspective-app/2478950/daily0.7https://beta.crstoday.com/news/corneat-vision-partners-with-liveu-and-alcon-for-remote-surgeon-virtual-presence/2478949/daily0.7https://beta.crstoday.com/news/glaukos-to-support-world-glaucoma-week-with-patient-education-campaign-and-free-screening-initiatives/2478945/daily0.7https://beta.crstoday.com/news/survey-suggests-people-living-with-glaucoma-at-increased-risk-of-sight-loss-and-blindness-due-to-covid-19-pandemic/2478946/daily0.7https://beta.crstoday.com/news/santen-emea-leads-awareness-campaign-to-prioritize-their-glaucoma-during-the-pandemic/2478942/daily0.7https://beta.crstoday.com/news/coopervision-introduces-2021-best-practices-honorees/2478943/daily0.7https://beta.crstoday.com/news/senate-narrowly-passes-covid-19-package-that-includes-aca-subsidy-boost-rural-hospital-money/2478944/daily0.7https://beta.crstoday.com/news/uk-four-other-countries-to-fast-track-vaccines-for-sars-cov-2-variants/2478939/daily0.7https://beta.crstoday.com/news/ocuphire-announces-publication-of-mira-1-phase-2b-results-demonstrating-reduction-of-pharmacologically-induced-mydriasis-by-nyxol/2478940/daily0.7https://beta.crstoday.com/news/sight-sciences-receives-fda-clearance-for-expanded-indication-for-omni-surgical-system/2478938/daily0.7https://beta.crstoday.com/news/hydrus-microstent-now-first-migs-device-with-5-year-pivotal-trial-data/2478937/daily0.7https://beta.crstoday.com/news/nicoxs-ncx-470-receives-approval-by-chinese-authorities-for-local-start-of-denali-phase-3-trial/2478936/daily0.7https://beta.crstoday.com/news/azura-ophthalmics-announces-positive-topline-results-from-phase-2-program-of-the-companys-investigational-treatment-for-mgd/2478934/daily0.7https://beta.crstoday.com/news/iridex-announces-strategic-collaboration-with-topcon-corporation/2478933/daily0.7https://beta.crstoday.com/news/haag-streit-diagnostics-to-host-online-education-events-as-part-of-its-perimetry-focus-month/2478932/daily0.7https://beta.crstoday.com/news/eyenovia-announces-fda-acceptance-of-the-mydcombi-nda/2478929/daily0.7https://beta.crstoday.com/news/trial-to-compare-efficacy-and-safety-outcomes-of-ab-interno-canaloplasty-for-glaucoma/2478931/daily0.7https://beta.crstoday.com/news/fda-accepts-oyster-points-filing-new-drug-application-for-oc-01-nasal-spray-for-the-treatment-of-signs-and-symptoms-of-dry-eye-disease/2478928/daily0.7https://beta.crstoday.com/news/glaucoma-uk-launches-new-services-booklet-for-people-living-with-glaucoma/2478926/daily0.7https://beta.crstoday.com/news/bio-tissue-receives-fda-clearance-to-proceed-with-clinical-study-using-investigational-new-drug-ttbt01/2478924/daily0.7https://beta.crstoday.com/news/jjs-covid-19-vaccine-wins-fda-authorization-for-emergency-use/2478921/daily0.7https://beta.crstoday.com/news/accure-therapeutics-enrolls-first-patient-in-phase-2-clinical-trial-on-acute-optic-neuritis/2478923/daily0.7https://beta.crstoday.com/news/zubisoft-launches-new-nomogram-and-laser-treatment-planner-for-zeiss-smile/2478920/daily0.7https://beta.crstoday.com/news/envision-announces-call-for-applications-for-next-class-of-research-fellows/2478919/daily0.7https://beta.crstoday.com/news/study-smartphones-could-help-to-prevent-glaucoma-blindness/2478918/daily0.7https://beta.crstoday.com/news/glaukos-announces-positive-phase-3-trial-results-for-ilink-epi-on-investigational-therapy/2478917/daily0.7https://beta.crstoday.com/news/remembering-george-marcellino-vice-president-of-marketing-and-clinical-affairs/2478916/daily0.7https://beta.crstoday.com/news/modernas-variant-specific-covid-19-vaccine-candidate-ready-for-clinical-testing/2478914/daily0.7https://beta.crstoday.com/news/allergan-submits-new-drug-application-for-investigational-eye-drop-for-the-treatment-of-presbyopia/2478915/daily0.7https://beta.crstoday.com/news/new-survey-assessment-finds-debilitating-impact-of-thyroid-eye-disease-ted-on-quality-of-life-continues-beyond-acute-disease-into-chronic-phase/2478913/daily0.7https://beta.crstoday.com/news/one-dose-jj-covid-19-vaccine-meets-criteria-as-safe-and-effective-fda-report-finds/2478912/daily0.7https://beta.crstoday.com/news/international-team-identifies-127-glaucoma-genes-in-largest-study-of-its-kind/2478911/daily0.7https://beta.crstoday.com/news/neuroptics-launches-virtual-pupillometry-education-platform/2478910/daily0.7https://beta.crstoday.com/news/vrmagic-eyesi-slit-lamp-fundoscopy-module-launched-in-the-uk/2478908/daily0.7https://beta.crstoday.com/news/pfizer-moderna-and-jj-tout-supercharged-covid-19-vaccine-output-eyeing-nearly-140-million-new-doses-by-march/2478909/daily0.7https://beta.crstoday.com/news/fci-ophthalmics-announces-availability-of-lacrijet-for-monocanalicular-nasolacrimal-intubation/2478907/daily0.7https://beta.crstoday.com/news/lexitas-announces-george-n-magrath-md-mba-assumes-role-of-chief-executive-officer/2478905/daily0.7https://beta.crstoday.com/news/topcon-announces-us-launch-of-the-harmony-glaucoma-module/2478906/daily0.7https://beta.crstoday.com/news/bausch-lomb-launches-alaway-preservative-free-antihistamine-eye-drops/2478902/daily0.7https://beta.crstoday.com/news/acufocus-submits-us-premarket-approval-application-to-the-fda-for-its-ic-8-small-aperture-iol/2478903/daily0.7https://beta.crstoday.com/news/optimo-medical-and-ansys-partner-announce-partnership-to-improve-surgery-preparation/2478904/daily0.7https://beta.crstoday.com/news/abbvie-launches-refresh-digital-lubricant-eye-drops/2478901/daily0.7https://beta.crstoday.com/news/nicox-announces-the-publication-of-preclinical-efficacy-results-on-a-new-class-of-non-pga-no-donating-iop-lowering-compounds/2478896/daily0.7https://beta.crstoday.com/news/re-vana-therapeutics-names-new-members-to-the-executive-team/2478897/daily0.7https://beta.crstoday.com/news/fda-outlines-faster-path-for-covid-19-vaccines-that-tackle-new-variants/2478898/daily0.7https://beta.crstoday.com/news/uk-real-world-data-show-covid-19-vaccine-linked-to-lower-infection-hospitalization-rates/2478899/daily0.7https://beta.crstoday.com/news/essilor-mourns-passing-of-bernard-maitenaz-inventor-of-the-first-varilux-progressive-lens/2478895/daily0.7https://beta.crstoday.com/news/bausch-health-to-reduce-debt-by-100-million-using-cash-generated-from-operations/2478894/daily0.7https://beta.crstoday.com/news/single-dose-of-pfizer-biontechs-covid-19-vaccine-85-effective-study/2478893/daily0.7https://beta.crstoday.com/news/the-vision-council-releases-results-of-january-2021-eyecare-provider-insights-survey/2478890/daily0.7https://beta.crstoday.com/news/ocuphire-initiates-enrollment-in-vega-1-phase-2-trial-investigating-nyxol-in-presbyopia/2478887/daily0.7https://beta.crstoday.com/news/pfizers-covid-19-vaccine-stimulates-lower-antibody-response-against-b-1-351-strain/2478888/daily0.7https://beta.crstoday.com/news/alcon-announces-broad-retail-availability-of-pataday-once-daily-relief-extra-strength-in-the-u-s/2478886/daily0.7https://beta.crstoday.com/news/ophtec-tiny-id-matrix-code-enables-fast-delivery-of-premium-cataract-iols/2478885/daily0.7https://beta.crstoday.com/news/ophthalmic-fundraising-activity-soars-in-face-of-pandemic/2478884/daily0.7https://beta.crstoday.com/news/eyevances-natacyn-now-available-next-day/2478883/daily0.7https://beta.crstoday.com/news/lion-eye-group-collaborates-with-ocli-spectrum-vision-partners/2478878/daily0.7https://beta.crstoday.com/news/analysis-roughly-2000-hospitals-fully-compliant-with-new-price-transparency-rule/2478879/daily0.7https://beta.crstoday.com/news/new-world-medicals-next-generation-kdb-glide-now-commercially-available/2478880/daily0.7https://beta.crstoday.com/news/jj-submits-single-dose-covid-19-vaccine-for-ema-review/2478881/daily0.7https://beta.crstoday.com/news/ocutrx-technologies-adds-to-its-surgical-visualization-suite-with-scopetrx-a-wireless-laparoscopic-swivel-camera/2478876/daily0.7https://beta.crstoday.com/news/real-world-use-analysis-backs-efficacy-of-pfizer-biontechs-covid-19-vaccine/2478875/daily0.7https://beta.crstoday.com/news/kala-pharmaceuticals-announces-eysuvis-now-covered-by-express-scripts/2478871/daily0.7https://beta.crstoday.com/news/icahn-to-push-for-changes-at-bausch-health-after-disclosing-stake/2478869/daily0.7https://beta.crstoday.com/news/inspecs-launches-sustainable-botaniq-eyewear-collection/2478870/daily0.7https://beta.crstoday.com/news/nicoxs-us-licensee-eyevance-expands-u-s-promotion-of-zerviate-in-agreement-with-hikma/2478867/daily0.7https://beta.crstoday.com/news/gensight-biologics-announces-publication-of-results-from-lumevoq-phase-1-2a-clinical-trial-reveal-in-biodrugs/2478868/daily0.7https://beta.crstoday.com/news/reichert-technologies-debuts-new-website-designed-to-improve-customer-experience/2478866/daily0.7https://beta.crstoday.com/news/akorn-receives-fda-approval-for-loteprednol-etabonate-ophthalmic-gel-0-5/2478864/daily0.7https://beta.crstoday.com/news/roches-actemra-reduces-deaths-in-hospitalized-covid-19-patients-study/2478863/daily0.7https://beta.crstoday.com/news/oculus-and-myopia-profile-aim-to-increase-knowledge-on-myopia/2478860/daily0.7https://beta.crstoday.com/news/trefoil-therapeutics-begins-second-phase-2-storm-clinical-trial-with-regenerative-treatment-for-fuchs-endothelial-corneal-dystrophy/2478856/daily0.7https://beta.crstoday.com/news/insurer-ducks-virus-coverage-claims-from-nj-eye-practice/2478857/daily0.7https://beta.crstoday.com/news/fda-clears-lillys-covid-19-antibody-duo-bamlanivimab-etesevimab-for-emergency-use/2478854/daily0.7https://beta.crstoday.com/news/focus-vitamins-unveils-new-blue-light-product-to-help-protect-eyes-from-digital-devices-and-eye-fatigue/2478855/daily0.7https://beta.crstoday.com/news/prevent-blindness-to-hold-16th-annual-eyes-on-capitol-hill-advocacy-event/2478850/daily0.7https://beta.crstoday.com/news/medicom-healthcare-signs-asset-purchase-agreement-of-bimatoprost-0-3-mg-ml-3ml/2478852/daily0.7https://beta.crstoday.com/news/palatin-technologies-announces-filing-of-international-patent-application-for-lead-compound-for-dry-eye-disease/2478853/daily0.7https://beta.crstoday.com/news/ocugen-and-bharat-biotech-announce-execution-of-definitive-agreement-for-the-commercialization-of-covaxin-in-the-us-market/2478849/daily0.7https://beta.crstoday.com/news/johnson-johnson-vision-celebrates-20-years-of-see-more-campaign-and-global-patient-story-search/2478846/daily0.7https://beta.crstoday.com/news/bausch-health-announces-vyzulta-is-now-approved-in-south-korea/2478847/daily0.7https://beta.crstoday.com/news/lumibird-medical-creates-three-nordics-subsidiaries/2478848/daily0.7https://beta.crstoday.com/news/euclid-systems-announces-expansion-of-leadership-team/2478845/daily0.7https://beta.crstoday.com/news/roche-files-for-fda-emergency-use-authorization-for-sars-cov-2-rapid-antigen-test/2478844/daily0.7https://beta.crstoday.com/news/heine-announces-launch-of-new-omega-600-lightweight-indirect-ophthalmoscope/2478842/daily0.7https://beta.crstoday.com/news/jcrs-publishes-phase-2-nepafenac-clinical-trial-with-evolute-sustained-drug-delivery-system/2478843/daily0.7https://beta.crstoday.com/news/early-data-find-astrazenecas-covid-19-vaccine-effective-against-fast-spreading-uk-strain/2478839/daily0.7https://beta.crstoday.com/news/jj-files-single-dose-covid-19-vaccine-for-us-emergency-use/2478836/daily0.7https://beta.crstoday.com/news/eye-health-america-acquires-three-optometric-practices-in-the-pee-dee-region-of-south-carolina/2478837/daily0.7https://beta.crstoday.com/news/aldeyra-therapeutics-announces-phase-3-tranquility-dry-eye-disease-trial-design/2478835/daily0.7https://beta.crstoday.com/news/gsk-curevac-partner-to-develop-mrna-vaccines-for-covid-19-variants/2478831/daily0.7https://beta.crstoday.com/news/jazz-to-buy-cannabinoid-drugmaker-gw-pharma-vva-7-2-billion-deal/2478832/daily0.7https://beta.crstoday.com/news/surface-ophthalmics-announces-first-patient-dosed-in-phase-2-trial-for-surf-200-for-acute-dry-eye/2478833/daily0.7https://beta.crstoday.com/news/santen-launches-ducressa-post-cataract-surgery-antibiotic-steroid-combination/2478828/daily0.7https://beta.crstoday.com/news/immunovant-announces-voluntary-pause-in-clinical-dosing-of-imvt-1401-for-thyroid-eye-disease/2478829/daily0.7https://beta.crstoday.com/news/states-need-more-supply-of-covid-19-vaccine-amid-push-to-grant-more-shots/2478827/daily0.7https://beta.crstoday.com/news/2021-ascrs-annual-meeting-moved-to-las-vegas-in-july/2478825/daily0.7https://beta.crstoday.com/news/fah-presses-for-32b-in-provider-assistance-in-next-covid-19-relief-package/2478821/daily0.7https://beta.crstoday.com/news/johnson-johnson-vision-receives-fda-approval-for-next-generation-monofocal-intraocular-lens-tecnis-eyhance-and-tecnis-eyhance-toric-ii-iols/2478822/daily0.7https://beta.crstoday.com/news/neurovision-imaging-receives-funding-from-the-addf-to-develop-biomarkers-to-diagnose-alzheimers-and-related-dementias/2478823/daily0.7https://beta.crstoday.com/news/alcon-canada-introduces-the-clareon-iol-with-the-autonome-preloaded-intraocular-lens-delivery-system/2478820/daily0.7https://beta.crstoday.com/news/horizon-therapeutics-to-acquire-viela-bio-to-grow-rare-disease-medicine-portfolio/2478819/daily0.7https://beta.crstoday.com/news/eu-authorizes-astrazenecas-covid-19-vaccine-amid-supply-dispute/2478816/daily0.7https://beta.crstoday.com/news/lensar-expands-board-of-directors-with-the-appointments-of-aimee-s-weisner-and-elizabeth-g-ofarrell/2478817/daily0.7https://beta.crstoday.com/news/jjs-single-dose-covid-19-vaccine-66-effective/2478814/daily0.7https://beta.crstoday.com/news/ocutrx-technologies-appoints-bill-link-phd-as-chairman-of-the-ocutrx-international-scientific-advisory-board/2478813/daily0.7https://beta.crstoday.com/news/novavaxs-covid-19-vaccine-over-89-effective-in-uk-trial-less-so-in-south-africa-study/2478809/daily0.7https://beta.crstoday.com/news/biden-to-sign-orders-to-establish-3-month-aca-sign-up-period-roll-back-trumps-medicaid-priorities/2478811/daily0.7https://beta.crstoday.com/news/johnson-johnson-vision-announces-peter-menziuso-as-the-new-worldwide-president-for-vision-care/2478812/daily0.7https://beta.crstoday.com/news/influence-of-patient-mask-wearing-on-ocular-injection-related-infection-unclear/2478807/daily0.7https://beta.crstoday.com/news/lilly-teams-up-with-gsk-vir-to-test-antibody-combination-against-covid-19/2478808/daily0.7https://beta.crstoday.com/news/verana-health-announces-real-world-data-and-data-science-collaboration-agreement-with-janssen/2478805/daily0.7https://beta.crstoday.com/news/surface-ophthalmics-announces-first-patient-dosed-in-head-to-head-phase-2-trial-for-surf-100-for-chronic-dry-eye-disease/2478802/daily0.7https://beta.crstoday.com/news/us-to-bolster-covid-19-vaccine-supply-with-millions-more-doses-this-summer/2478803/daily0.7https://beta.crstoday.com/news/regenerons-antibody-cocktail-shows-promise-as-passive-vaccine-against-covid-19/2478804/daily0.7https://beta.crstoday.com/news/neurophth-therapeutics-appoints-qiutang-li-phd-as-chief-scientific-officer/2478800/daily0.7https://beta.crstoday.com/news/google-commits-150m-to-covid-19-vaccine-education-partnering-with-one-medical-to-open-vaccination-sites/2478801/daily0.7